首頁 > 市場調查報告書 > 製藥

神經疾病

中樞神經系統（CNS）治療市場規模、佔有率和成長分析（按疾病、藥物類別、通路和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1898041

中樞神經系統（CNS）治療市場規模、佔有率和成長分析（按疾病、藥物類別、通路和地區分類）－2026-2033年產業預測

CNS (Central Nervous System) Therapeutics Market Size, Share, and Growth Analysis, By Disease (Neurovascular Diseases, CNS Trauma), By Drug Class (Anesthetics, Anticonvulsants), By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月17日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，中樞神經系統 (CNS) 治療市場規模將達到 1,449.6 億美元，到 2025 年將達到 1,540.9 億美元，到 2033 年將達到 2,512.2 億美元，預測期（2026-2033 年）的複合年成長率為 6.3%。

中樞神經系統（CNS）治療市場是醫療保健和製藥行業的重要組成部分，為神經系統和精神疾病提供廣泛的治療方案。隨著人們對中樞神經系統複雜性的認知不斷加深，以及對心理健康挑戰日益關注和人口老化帶來的持續創新，推動了該領域的成長。製藥公司和研究機構之間的合作正在推動治療方法的進步。儘管該市場具有顯著改善患者生活品質的潛力，但也面臨監管核准流程、定價趨勢和競爭壓力等挑戰。相關人員必須制定策略，應對這些挑戰，才能最大限度地掌握這個不斷發展的市場所帶來的機會。

中樞神經系統（CNS）治療市場促進因素

全球人口老化導致阿茲海默症和帕金森氏症等神經系統疾病的發生率顯著上升。由於老年人更容易患上這些疾病，這種人口結構變化顯著增加了對中樞神經系統的治療方案的需求。因此，這些疾病盛行率的不斷上升推動了對先進的中樞神經系統治療方法和創新療法的需求，凸顯了有效醫療干預措施以滿足日益成長的患者群體需求的緊迫性。解決神經系統健康問題至關重要，因為它與提高老年人生活品質的更廣泛目標相契合。

中樞神經系統（CNS）治療市場限制因素

由於用於治療神經和精神疾病的藥物研發過程漫長，中樞神經系統（CNS）治療市場面臨嚴峻的挑戰。全面的臨床試驗和嚴格的監管審查往往導致研發延誤，並加重企業的財務負擔。這些障礙阻礙了創新，使得新治療方法難以快速上市。因此，監管合規的複雜性可能會延緩突破性CNS療法的研發和核准，這可能會減少患者獲得有效治療的機會。

中樞神經系統（CNS）藥物市場趨勢

隨著基因和神經影像技術的進步，人們對中樞神經系統（CNS）疾病的個體差異有了更深入的了解，CNS治療市場正加速向個人化醫療轉型。這一趨勢著重於根據患者特定的基因組成、神經生物學特徵和治療反應來客製化治療策略，從而實現更精準有效的干涉。因此，個人化醫療可望改變阿茲海默症、憂鬱症和思覺失調症等常見疾病的治療模式，最終改善患者預後，並推動CNS治療領域的成長。這種變革有望提高療效，減少副作用，從而在神經病學領域建立一種更以患者為中心的治療方法。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Biogen（United States）
Otsuka Pharmaceutical Co., Ltd.（Japan）
Eli Lilly and Company（United States）
Merck & Co., Inc.（United States）
AstraZeneca（United Kingdom）
Takeda Pharmaceutical Company Limited（Japan）
Novartis AG（Switzerland）
Teva Pharmaceutical Industries Ltd.（Israel）
Johnson & Johnson Services, Inc.（United States）
Pfizer Inc.（United States）
Sanofi SA（France）
H. Lundbeck A/S（Denmark）
UCB SA（Belgium）
PTC Therapeutics（United States）
Jazz Pharmaceuticals plc（Ireland）
Acadia Pharmaceuticals, Inc.（United States）
Neumora Therapeutics（United States）
Immunic Therapeutics（United States）
Muna Therapeutics（Denmark）
NRG Therapeutics（United Kingdom）

結論與建議

簡介目錄

Product Code: SQMIG35H2239

CNS (Central Nervous System) Therapeutics Market size was valued at USD 144.96 Billion in 2024 and is poised to grow from USD 154.09 Billion in 2025 to USD 251.22 Billion by 2033, growing at a CAGR of 6.3% during the forecast period (2026-2033).

The Central Nervous System (CNS) Therapeutics market represents a vital segment of the healthcare and pharmaceutical landscape, offering a myriad of treatments for neurological and psychiatric disorders. As the complexities of the CNS are increasingly understood, the sector benefits from continuous innovation driven by heightened awareness of mental health challenges and a growing elderly population. Collaborative efforts between pharmaceutical companies and research organizations are propelling advancements in therapeutic methods. While the market showcases potential for significantly enhancing the quality of life for affected individuals, it also encounters hurdles such as regulatory approval processes, pricing dynamics, and competitive pressures. Stakeholders must strategically navigate these challenges to capitalize on the opportunities presented within this evolving market.

Top-down and bottom-up approaches were used to estimate and validate the size of the CNS (Central Nervous System) Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

CNS (Central Nervous System) Therapeutics Market Segments Analysis

Global CNS (Central Nervous System) Therapeutics Market is segmented by Disease, Drug Class, Distribution Channel and region. Based on Disease, the market is segmented into Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer and Others. Based on Drug Class, the market is segmented into Anesthetics, Anticonvulsants, Antiemetics, CNS Stimulants, Pain Relievers and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the CNS (Central Nervous System) Therapeutics Market

The increasing aging population globally contributes to a notable rise in the incidence of neurological disorders, such as Alzheimer's and Parkinson's disease. This demographic transition significantly enhances the need for therapeutic solutions targeting the central nervous system, as the elderly are more vulnerable to these ailments. Consequently, the growing prevalence of these disorders drives the demand for advanced CNS therapies and innovative treatments, highlighting the urgency for effective medical interventions tailored to meet the needs of this expanding patient population. The focus on addressing neurological health is paramount, as it aligns with the broader goal of improving quality of life among aging individuals.

Restraints in the CNS (Central Nervous System) Therapeutics Market

The CNS Therapeutics market faces significant challenges due to the lengthy process of developing drugs for neurological and psychiatric conditions. The necessity for comprehensive clinical trials and the strict evaluations by regulatory bodies often result in delays and increased financial burdens for companies. These obstacles can stifle innovation, making it more difficult to introduce new therapies promptly. Consequently, patient access to effective treatments may be adversely affected, as the complexities of regulatory compliance slow down the development and approval of potentially life-changing therapeutics in the Central Nervous System sector.

Market Trends of the CNS (Central Nervous System) Therapeutics Market

The Central Nervous System (CNS) therapeutics market is increasingly leaning towards personalized medicine, driven by advancements in genetics and neuroimaging technologies that enhance the understanding of individual variations in CNS disorders. This trend focuses on customizing treatment strategies based on a patient's specific genetic makeup, neurobiological characteristics, and therapeutic responses, promoting more precise and effective interventions. As a result, personalized approaches are expected to transform the treatment paradigm for prevalent conditions such as Alzheimer's disease, depression, and schizophrenia, ultimately improving patient outcomes and driving growth within the CNS therapeutics sector. This evolution can lead to better efficacy and reduced side effects, shaping a more patient-centered approach in neurology.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global CNS (Central Nervous System) Therapeutics Market Size by Disease & CAGR (2026-2033)

Market Overview
Neurovascular Diseases
CNS Trauma
Mental Health
- Anxiety Disorders
- Epilepsy
- Mood Disorders
- Psychotic Disorders
- Others
Neurodegenerative Diseases
- Alzheimer's Disease
Parkinson's Disease
- Multiple Sclerosis
- Huntington's Disease
Amytrophic Lateral Sclerosis
- Others
Infectious Diseases
CNS Cancer
Others

Global CNS (Central Nervous System) Therapeutics Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Anesthetics
Anticonvulsants
Antiemetics
CNS Stimulants
Pain Relievers
Others

Global CNS (Central Nervous System) Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Others

Global CNS (Central Nervous System) Therapeutics Market Size & CAGR (2026-2033)

North America (Disease, Drug Class, Distribution Channel)
- US
- Canada
Europe (Disease, Drug Class, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Disease, Drug Class, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Disease, Drug Class, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Disease, Drug Class, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Biogen (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Services, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
H. Lundbeck A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A. (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PTC Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jazz Pharmaceuticals plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Acadia Pharmaceuticals, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Neumora Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Immunic Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Muna Therapeutics (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NRG Therapeutics (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments